SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Marc Kahn who wrote (232)7/14/1998 9:22:00 AM
From: James Strauss  Read Replies (1) | Respond to of 534
 
Marc:

Excellent post!!!

It does look like Bioject Mgmt is on the right marketing track... Last year there was 1.3 million in Revenues for the first two Qtrs... This Merck deal gives them 1.5 million in the second Qtr plus whatever they did in the first Qtr... It looks like the Revenue stream is starting to accelerate... I expect Bioject will now be in the news more frequently as it continues moving in the direction of becoming the vaccine delivery system of choice...

Jim



To: Marc Kahn who wrote (232)7/14/1998 9:06:00 PM
From: Fletcher P. Grundmann  Read Replies (3) | Respond to of 534
 
Very interesting thread.

Bioject has a great product. Period. But, BJCT is too small. This company is going to be bankrupt in a year unless acquired, and someone else is going to take this technology to market. Don't waste your money (not, yet)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News